Piper Jaffray reiterates its Buy rating and $50 price target on OSI Pharmaceuticals (Nasdaq: OSIP).

The firm ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE